Anti-BAP1 antibody (AA37224)

$187.00


Alternative names Ubiquitin carboxyl-terminal hydrolase BAP1, EC 3.4.19.12, BRCA1-associated protein 1, Cerebral protein 6, BAP1, KIAA0272, hucep-6, BAP1_HUMAN, Q92560, 8314
Source 729
Species Reactivity Human, Mouse, Rat
Applications IF/ICC, IHC, WB
Host Rabbit
Class Polyclonal
Conjugated Unconjugated


Description

Product name Anti-BAP1 antibody (AA37224)
Catalog number AA37224
Brand family Ango
Product type Primary Antibody
Antibody Alternative Names Ubiquitin carboxyl-terminal hydrolase BAP1 antibody, EC 3.4.19.12 antibody, BRCA1-associated protein 1 antibody, Cerebral protein 6 antibody, BAP1 antibody, KIAA0272 antibody, hucep-6 antibody, BAP1_HUMAN antibody


Biological Information

Immunogen Recombinant protein of human BAP1
Concentration 1 mg/ml
Isotype IgG
Application Notes WB 1:500 - 1:2000 IHC 1:50 - 1:200 IF 1:50 - 1:200
Purification method Purified by affinity chromatography


Target

Target Name BAP1
SwissProt ID Link Q92560
Function Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1). Does not deubiquitinate monoubiquitinated histone H2B. Acts as a regulator of cell growth by mediating deubiquitination of HCFC1 N-terminal and C-terminal chains, with some specificity toward 'Lys-48'-linked polyubiquitin chains compared to 'Lys-63'-linked polyubiquitin chains. Deubiquitination of HCFC1 does not lead to increase stability of HCFC1. Interferes with the BRCA1 and BARD1 heterodimer activity by inhibiting their ability to mediate ubiquitination and autoubiquitination. It however does not mediate deubiquitination of BRCA1 and BARD1. Able to mediate autodeubiquitination via intramolecular interactions to couteract monoubiquitination at the nuclear localization signal (NLS), thereby protecting it from cytoplasmic sequestration (PubMed:24703950). Acts as a tumor suppressor.
Subcellular Location Cytoplasm. Nucleus. Mainly nuclear. Binds to chromatin. Localizes to the cytoplasm when monoubiquitinated by the E2/E3 hybrid ubiquitin-protein ligase UBE2O (PubMed:24703950).
Involvement in Disease Mesothelioma, malignant: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. The gene represented in this entry is involved in disease pathogenesis. Tumor predisposition syndrome: A condition characterized by predisposition to develop a variety of tumors, including benign melanocytic tumors as well as several malignant tumors, including uveal melanoma, cutaneous melanoma, malignant mesothelioma on exposure to asbestos, lung adenocarcinoma and meningioma. The disease is caused by mutations affecting the gene represented in this entry.
Post-Translational Modification Ubiquitinated: monoubiquitinated at multiple site of its nuclear localization signal (NLS) BY UBE2O, leading to cytoplasmic retention. Able to mediate autodeubiquitination via intramolecular interactions to couteract cytoplasmic retention.
Tissue Specificity Highly expressed in testis, placenta and ovary. Expressed in breast.
Subunit Structure Component of the PR-DUB complex, at least composed of BAP1 and ASXL1. Interacts with BRCA1 (via the RING finger). Interacts (via HBM-like motif) with HCFC1.
Sequence Similarities Belongs to the peptidase C12 family. BAP1 subfamily.


Poduct Presentation

Form Liquid
Preservative 0.02% (w/v) sodium azide
Storage buffer PBS with 50% glycerol, pH 7.3


Storage and Shipping Information

Storage Store at -20 or -80 C. Avoid multiple freeze/thaw cycles.